ReviewFrontiers in endocrinology2025
An expert narrative review on the mechanisms and therapeutic potential of gut microbiota-derived metabolites in multi-organ crosstalk.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plant Foods as Healthy Sources of Dietary Fibre, Microbiota Modulation and Bioactive Compounds: Beyond Definitions-A Review.Nutrients · 2026Review
- Targeting the cardio-neuro axis through nutrition: inflammatory mechanisms linking cardiovascular and neurodegenerative diseases.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gut microbiota-derived metabolites-short-chain fatty acids (SCFAs), tryptophan derivatives, and uremic toxins-translocate systemically and mediate multi-organ crosstalk along the gut-kidney-heart-brain-endocrine axis, influencing host physiology and disease. However, integrated mechanistic insights remain limited. Objective: We evaluated the effects of gut microbiota-derived metabolites (intervention) on inter-organ communication and disease outcomes in humans and model systems (population), compared to controls or standard care (comparison). Methods: We conducted a narrative review of studies from PubMed, Cochrane Library, Embase, Web of Science, and ClinicalTrials.gov (2020-2025). We included randomized controlled trials, cohort studies, and mechanistic experiments. Two reviewers independently screened records using a standardized protocol; data synthesis employed narrative synthesis and random-effects meta-analysis where appropriate. Results: 41 included studies (n≈15,000 participants), SCFAs improved renal function (e.g., risk ratio [RR]=0.85 for composite outcomes, 95% CI: 0.72-0.98) with substantial heterogeneity (I²=68%). SCFAs conferred cardio protection and regulated neuroinflammation. Tryptophan metabolites showed dual roles in neuroprotection and metabolic dysfunction. Metabolites demonstrated diagnostic value (e.g., TMAO AUC = 0.87 for cardiovascular risk). Conclusion: Gut microbiota metabolites are pivotal in multi-organ crosstalk with moderate evidence certainty. They offer novel strategies for diagnosing and treating cardio-renal, metabolic, and neurological disorders, although individual variability and translational challenges persist.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.